|
Match
|
Document |
Document Title |
|
|
7390489 |
Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes , a hybridoma cell producing the monoclonal antibody, a test kit comprising...
|
|
|
7381412 |
Anti-TECK antibodies and methods of use therefor
The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also...
|
|
|
7374765 |
Methods and compositions for diagnosis and treatment of iron misregulation diseases
Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and...
|
|
|
7374760 |
Methods and compositions for nerve regeneration
Methods and compositions for modulating growth of a neuron with a Wnt, a Wnt-like substance, and/or a chemical compound affecting a Wnt signaling pathway are disclosed. Also disclosed are methods...
|
|
|
7371381 |
Anti-galanin antibodies and uses thereof
The present invention provides antibodies that immunospecifically bind to a galanin peptide and compositions comprising said antibodies. The present invention also provides methods for preventing,...
|
|
|
7371379 |
Dosages for treatment with anti-ErbB2 antibodies
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or...
|
|
|
7371378 |
Modified human IGF-IR antibodies
The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention...
|
|
|
7368543 |
Diagnosis and treatment of hepatic disorders
The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration...
|
|
|
7368106 |
Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40...
|
|
|
7361345 |
Anti-CD40 antibodies capable of blocking B-cell activation
Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen...
|
|
|
7361341 |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
|
|
|
7357927 |
Death domain containing receptors
The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated...
|
|
|
7354762 |
Method for producing CE7-specific redirected immune cells
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular...
|
|
|
7354586 |
Methods of treating arthritis and diabetic retinopathy with αvβ3-specific antibodies
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
7354583 |
Antibody-induced apoptosis
Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also...
|
|
|
7354577 |
Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof
A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial...
|
|
|
7348001 |
Tie1-binding ligands
Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that...
|
|
|
7338660 |
Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7332580 |
Bispecific single chain Fv antibody molecules and methods of use thereof
Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
|
|
|
7332162 |
Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
A ligand derived from, e.g. a Fab fragment of, a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-organisms under accession number LMBP...
|
|
|
7332157 |
Methods for human allografting
A method of preparing a human recipient for a graft from a human which includes: inducing mixed chimerism in the recipient (e.g., by administering to the recipient irradiation or chemotherapy),...
|
|
|
7329406 |
Methods of treating psoriasis with αvβ3-specific antibodies
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
7326415 |
Antibodies to non-functional P2X7 receptor
The present invention provides antibodies that specifically bind to P2X 7 receptors and distinguish between functional and non-functional P2X7 receptors, pharmaceutical compositions and kits...
|
|
|
7323171 |
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
|
|
|
7323170 |
Anti-CD80 antibodies
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from...
|
|
|
7320792 |
Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
A preventive and therapeutic agent for psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.
|
|
|
7320786 |
Photodynamic therapy treatment for eye disease
This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light...
|
|
|
7314623 |
Methods and compositions for modulating T helper (Th) cell development and function
Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
|
|
|
7314619 |
Inducing apoptosis using anti-Apo-2 antibodies
Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also...
|
|
|
7311911 |
Methods for inhibiting angiogenesis
The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with the specific binding of...
|
|
|
7311910 |
Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing...
|
|
|
7309489 |
Mouse CD40 ligand-specific antibodies and hybridomas
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
7306800 |
Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal...
|
|
|
7291332 |
Inflammatory mediator antagonists
The present invention relates to the use of an antagonist of OSM such as an antibody or small molecule in the manufacture of a medicament for the treatment or prophylaxis of an inflammatory...
|
|
|
7288638 |
Fully human antibodies against human 4-1BB
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody....
|
|
|
7288252 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7288251 |
Antibodies to CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7285267 |
Tumor necrosis factor receptors 6α & 6β
The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α &...
|
|
|
7279160 |
Combinations of DR5 antibodies and other therapeutic agents
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and...
|
|
|
7273924 |
Antibodies to the ED-B domain of fibronectin, their construction and uses
A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN).
|
|
|
7270817 |
ACPL antibodies and methods of use thereof
The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides,...
|
|
|
7265209 |
CE7-specific chimeric T cell receptor
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular...
|
|
|
7264967 |
Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
The present invention provides an antibody which specifically recognizes an epitope containing a part of a domain based on a finding that the domain ranging from the 269- to 315-positions of human...
|
|
|
7264805 |
Proteins with a high immunoreactivity and a method for the production thereof
The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced...
|
|
|
7259247 |
Anti-human T-cell costimulating polypeptide monoclonal antibodies
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the...
|
|
|
7258859 |
Method for the treatment of multiple sclerosis
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to...
|
|
|
7258857 |
Rage-related methods for treating inflammation
The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount...
|
|
|
7255854 |
Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly...
|
|
|
7252994 |
Human DR4 antibodies and uses thereof
Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis...
|
|
|
7244832 |
Humanised antibodies
CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or...
|